Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
ConclusionsAdults and adolescents with moderate-to-severe atopic dermatitis treated with once-daily upadacitinib 15 or 30 mg experienced early improvements in itch, pain, other skin symptoms, sleep, quality of life, and mental health that were sustained through week 52.Clinical Trial RegistrationClinicalTrials.gov identifiers NCT03569293 (13 August 2018) and NCT03607422 (27 July 2018). (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 25, 2024 Category: Dermatology Source Type: research
Association between helminth infection and allergic disorders among children in Batu, Ethiopia
Conclusion and clinical relevanceThis study found a non-significant inverse association between helminths infection and atopy and allergic disorders, likely due to reduced statistical power, resulting in a lower prevalence of atopy and allergic conditions. A high powered longtitudinal study is necessary to explore the casuality and potential therapeutic benefits of helminths for allergic disorders. (Source: Immunity, Inflammation and Disease)
Source: Immunity, Inflammation and Disease - March 23, 2024 Category: Allergy & Immunology Authors: Sosina Walelign,
Mheret Tesfaye,
Geremew Tasew,
Kassu Desta,
Aster Tsegaye,
Bineyam Taye Tags: ORIGINAL ARTICLE Source Type: research
